Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cipla Signals US Launch Momentum, Commodity-Like Price Cycle

Executive Summary

Cipla's US business appears set to gain momentum with a string of differentiated generic launches lined up and the firm's CEO shares key insights into how price peaks and troughs could potentially play out in the world's largest pharmaceutical market.

You may also be interested in...



Cipla Primes For US Momentum But Seretide Generic Is Slow In UK

Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.

Cipla Primes For US Momentum But Seretide Generic Is Slow In UK

Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.

Asia Executives To Watch: Novartis China, GSK India, Cipla

Novartis’s former head of West China is moving to lead its global cardio-metabolic franchise, while GSK India and Cipla have made key personnel appointments on the manufacturing front.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel